August 2012
-
The Indian Ministry of Science & Technology’s Technology Development Board (TDB) has signed a development and commercialization agreement with Hyderabad-based Sapigen Biologix, committing ₹100 crores to development of a novel intranasal vaccine against COVID-19 and… Read more . . .
-
CyanVac subsidiary Blue Lake Biotechnology is planning a Phase 1 trial of its BLB-201 intranasal vaccine against respiratory syncytial virus (RSV) after receiving FDA clearance for its IND, CyanVac said. The Phase 1 trial will… Read more . . .
-
OxyContin maker Purdue Pharma will provide an additional $11 million to non-profit Harm Reduction Therapeutics (HRT) for continued development of HRT’s HRT001 naloxone nasal spray for the reversal of opioid overdose. The additional funding was… Read more . . .
-
Virpax has announced an expansion of its license agreement with Nanomerics to add worldwide rights to AnQlar nasal spray, an antiviral mucoadhesive polymer derived from chitosan. The original license agreement, which was announced in August… Read more . . .
-
Inhaled lactose manufacturer DFE Pharma, API manufacturer Sterling, and filling/packaging company Harro Höfliger have partnered to create an early development service for DPIs called “INTO” (Inhalation Together). According to the INTO web site, the partnership… Read more . . .
-
Researchers from the Karolinska Institutet and Louisiana State University (LSU) Health New Orleans have published an article describing positive effects of intranasal delivery of a cocktail of five different pro-resolving lipid mediators in a mouse… Read more . . .
-
Funds managed by Oaktree Capital Management will provide $100 million in funding to Impel NeuroPharma, with $50 million of that amount in cash up front as part of a royalty agreement on net sales of… Read more . . .
-
According to Ji Xing Pharmaceuticals, Chinese regulators have approved the company’s application for a Phase 3 clinical trial of OC-01 varenicline nasal spray for the treatment of dry eye disease in China. Ji Xing acquired… Read more . . .
-
A Swiss-German consortium led by Volker Thiel of the Institute of Virology and Immunology and the University of Bern has partnered with Swiss startup RocketVax to develop two live attenuated intranasal vaccine candidates against SARS-CoV-2… Read more . . .
-
Pulmatrix has announced that topline data from a Phase 1b study of its PUR1800 dry powder narrow spectrum kinase inhibitor in COPD patients showed that inhaled PUR1800 produced “low and consistent systemic exposure” with “no… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.